Roche en route to first continuous delivery treatment for nAMD in Europe
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
List view / Grid view
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
The ocular injection, now granted its third FDA approval, offers a more convenient treatment option for patients with vision loss.
In its latest meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended 12 medicines for approval, including those for rare diseases, osteoporosis and cancer.
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.